Clinical Benefit in NSCLC: Advanced-Stage Patients Require Symptom-Improving Palliation. Experiences from the ‘Iressa’ Expanded Access Program

Publisher： Karger

E-ISSN： 2296-5262|28|4|195-198

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.4, 2005-10, pp. : 195-198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 340-347

Karger

Access to resources Recommend Favorite

Effect of Imatinib Mesylate Combined with Granulocyte Colony-Stimulating Factor on Leukaemic Blast Cells Derived from Advanced-Stage Chronic Myelogenous Leukaemia Patients

By  

Acta Haematologica, Vol. 116, Iss. 1, 2006-07 ,pp. : 8-18

Karger

Access to resources Recommend Favorite

Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe

By  

Oncology Research and Treatment, Vol. 34, Iss. 5, 2011-04 ,pp. : 233-238

Karger

Access to resources Recommend Favorite

Patients’ experiences from symptom onset to initial treatment for atrial fibrillation

By  

JOURNAL OF CLINICAL NURSING, Vol. 24, Iss. 5-6, 2015-03 ,pp. : 786-796

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stanford V Regimen plus Consolidative Radiotherapy Is an Effective Therapeutic Program for Bulky or Advanced-Stage Hodgkin’s Disease

By  

Acta Haematologica, Vol. 112, Iss. 3, 2004-09 ,pp. : 141-147

Karger

Access to resources Recommend Favorite